Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Go back to Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
(NASDAQ: GMAB) Delayed: 39.57 +0.50 (1.28%)
Previous Close $39.07    52 Week High $ 
Open $39.08    52 Week Low $ 
Day High $39.66    P/E N/A 
Day Low $39.05    EPS $ 
Volume 3,106,117